PMID: 3747721Sep 22, 1986Paper

Mescaline-induced motor impairment in rats, assessed by two different methods

Life Sciences
E A Sykes

Abstract

Motor impairment, especially ataxia, is often mentioned as a 'side effect' of doses of psychoactive drugs which depress animal behaviour; it is difficult to determine it accurately from visual observation, but relatively few attempts have been made to measure it objectively and quantitatively. Mescaline, in moderate to large doses, can induce biphasic--depressant followed by stimulant--effects on learnt and other performance of laboratory rodents. Motor impairment, using three doses, was accordingly measured during the depressant phase by two methods. An 'ataxia' test, involving analyses of footprints, showed few irregularities of gait splay due to mescaline, but the drug markedly reduced the length of steps ('stride') in a dose-related manner. In a 'tilt plane' test for general motor control, the animals' ability to cling to a tilted plane decreased with 25 mg/kg mescaline, at 30 and 40 minutes after administration. Deficits of this kind can be relevant to interpreting drug actions on forms of behaviour which involve movements for responding, and they also have interesting potential in their own right.

References

Sep 1, 1979·Psychopharmacology·M A GeyerR L Hawkins
Jul 9, 1979·Life Sciences·R E HruskaE K Silbergeld
Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·A Delini-StulaP R Hedwall
Sep 18, 1978·Life Sciences·W M BournJ F Bonfiglio
Jun 1, 1977·Toxicology and Applied Pharmacology·P M Edwards, V H Parker
Aug 1, 1975·Experimental Neurology·P MullenixB Culver
Sep 11, 1964·Psychopharmacologia·J R Smythies, E A Sykes
Nov 1, 1980·Acta Pharmacologica Et Toxicologica·S B Ross
Jan 1, 1984·Annual Review of Pharmacology and Toxicology·H A Tilson, C L Mitchell
Jan 1, 1981·Psychopharmacology·J L GibbonsW H Bridger
Jan 1, 1982·Pharmacology, Biochemistry, and Behavior·M L Elliott, R J Sbordone
Aug 29, 1959·Nature·H WALLGREN

❮ Previous
Next ❯

Citations

Apr 1, 1989·Journal of Pharmacological Methods·H SteinbergH Tillotson
Feb 17, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomás PálenícekJirí Horácek
Jan 19, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Evan J KyzarAllan V Kalueff
Dec 21, 2010·Pharmacology, Biochemistry, and Behavior·Tomáš PáleníčekCyril Höschl
May 3, 2007·Rapid Communications in Mass Spectrometry : RCM·Jin Young KimMoon Kyo In
Jun 1, 2017·International Journal of Technology Assessment in Health Care·Esther JacobsMichaela Eikermann
May 31, 2018·ACS Chemical Neuroscience·Bruce K Cassels, Patricio Sáez-Briones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.